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ABSTRACT
The number of immunocompromised patients is rising, and immunodeficiency is an independent risk factor for the devel-
opment of premalignant and malignant lesions of the cervix and anogenital tract. The aim of this review was to summarize 
and update data on human papilloma virus (HPV) infections and HPV-based anogenital lesions detected in patients who 
were immunocompromised due to both organ transplantation and human immunodeficiency virus (HIV) infection. The 
incidence of HPV infections among solid organ recipients and HIV positive females is reported to be significantly higher when 
compared with age-matched healthy controls- i.e. higher by up to 65% and 46.6% respectively, vs 38% in the controls. These 
infections are also more often chronic, high risk HPV and multitype. Data suggest that HPV infections in these patients 
might not only occur more frequently, but that the course of the infection might also lead to faster oncogenesis. However, 
the treatment options for malignancies are limited; and this implies the need for intense primary and secondary prevention 
regimens. As infections with HPV types other than 16 and 18 and multitype infections are particularly frequently discovered 
in immunocompromised patients, they would probably benefit most from a nonavalent vaccine. Gynecological screening 
should be performed annually, including cervical smears and/ or HPV testing. In the group of non-responders, self-sampling 
methods should be considered.
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INTRODUCTION
For years, the greatest concern regarding patients treat-
ed with transplantation for end-stage organ failure was to 
sustain the graft function in order to lengthen patients’ life 
expectancy. Nowadays, solid organ rejections are success-
fully prevented with maintenance treatment based on com-
binations of immunosuppressive drugs such as calcineurin 
inhibitors (cyclosporine, tacrolimus), corticosteroids and ad-
juvant drugs (mycophenolate mofetil, azathioprine or mam-
malian target of rapamycin-mTOR inhibitors e.g., sirolimus, 
everolimus) thus improving patients’ survival rates. Recent 
clinical observations indicate that life expectancy depends 
more on factors secondary to life-long immunosuppressive 
therapy and the increasing age of this transplant popula-
tion, such as cardiovascular diseases or malignancies, and 
especially those driven by viral infections. It is estimated 
that in the next decade, mortality due to malignancies will 
exceed that from cardiovascular diseases in the population 
of renal transplant recipients [1].
Immunodeficiency is a well-established risk factor for de-
veloping human papilloma virus (HPV)-related premalignant 
and malignant lesions of the lower genital tract and anogenital 
region [2, 3]. HPV infections are frequently observed in the 
general population, with up to 80% of women reported as 
experiencing such infections during their lifetime. These in-
fections are however usually transient, and authors estimate 
that about 70% of immunocompetent individuals are clear 
of the infection within 12 months, and 91% are clear within 
24 months, with the mean duration of the infection between 
8 and 13 months [4]. On the other hand, immunocompromised 
patients are prone to experiencing chronic HPV infections, 
and the reasons for this persistence are not fully understood. 
Immunodeficiency (immunosuppression or immuno-
compromise) results from any of three main reasons: viral 
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infections as in human immunodeficiency virus (HIV) positive 
patients or in patients with acquired immune deficiency syn-
drome (AIDS); from the use of immunosuppressive drugs by 
such as solid organ transplant recipients (e.g., renal transplant 
recipients (RTRs), or liver transplant recipients (LTRs) and/or 
in patients with connective tissue diseases (e.g., systemic 
lupus erythematosus, or systemic scleroderma); and also in 
rare cases of primary immunodeficiency disease. Immunode-
ficiency in both HIV/AIDS patients and solid organ recipients 
was proved to be an independent risk factor for developing 
various malignancies, including HPV-related malignancies [2]. 
Buell et al. [1] estimated that after 10 years of immunosup-
pression, the risk of malignancy reaches 20%, which is three- 
to fivefold higher than in the general population. 
Hinten et al. [5], in a review published in 2012, ana-
lyzed HPV-related premalignant and malignant lesions of 
the female anogenital tract in RTRs. In our mini-review, we 
aimed to combine and update data on HPV infections and 
HPV-based anogenital lesions detected in immunocom-
promised patients due to both organ transplantation and 
HIV infection. To do this, we searched the PubMed data-
base looking for information on “human papilloma virus” 
or “HPV” and “immunosuppression” or “immunodeficiency” 
or “transplantation” or “HIV” and “cancer” or “malignancy” or 
“neoplasia”. References included in the articles thus retrieved 
were also reviewed to identify further articles corresponding 
with our analysis topic.
HUMAN PAPILLOMA VIRUS (HPV)
Over 200 types of HPV have been discovered so far; and 
we distinguish between cutaneous subtypes connected 
with the formation of verrucae and mucosal subtypes that 
are mostly responsible for the development of lesions in 
the anogenital region. The latter are further divided into 
low-risk HPV subtypes (lrHPV: 6, 11, 27, 32, 42, 53, 54, 57, 61, 
62, 69, 71, 72, 81, 83, 84, 86, 87, 89, 90, 102, 106), high-risk 
HPV subtypes (hrHPV: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 
58, 59, 66), and HPV subtypes of unknown risk (subtypes 26, 
30, 34, 53, 67, 68, 69, 70, 73, 82, 85 and 97) that are further 
investigated to assess their oncogenic potential and that are 
usually considered to be potentially high-risk subtypes [6].
The most-studied subtypes that are linked with the crea-
tion of anogenital malignancies are hrHPV types 16 and 18, 
and they are said to be responsible for approximately 70% of 
cervical cancers and precancerous lesions [7]. Another 20% of 
cervical cancers are related to hrHPV types 31, 33, 35, 45, 52 and 
58 [8]. Studies have shown that HIV infection might influence 
the carcinogenicity of hrHPV types and therefore, the detec-
tion rates of invasive cervical carcinoma attributable to HPV 
16 might be lower in HIV-positive females, with concomitantly 
higher detection rates of cancers attributable to HPV 18. Some 
authors have claimed that acquisition of HPV 16 is less affected 
by the CD4 cell count than the acquisition of other hrHPV 
types; and this might indicate the existence of mechanisms 
that enable HPV 16 to avoid immune surveillance, and as such, 
it is something that requires further investigation [8].
INCIDENCE
The incidence of HPV infections among both solid organ re-
cipients and HIV-positive females are reported to be signifi-
cantly higher than among age-matched healthy controls: up to 
65% and up to 46.6% vs 38% respectively [9, 10]. The infections 
are also more often hrHPV and multitype infections. Data sug-
gest that HPV infections in these patients might not only occur 
more frequently, but that their course might also lead to faster 
oncogenesis [11]. It was proved in a study by Adebamowo et al., 
that HIV-positive females, when compared with HIV-negative 
subjects presented a significantly higher prevalence of lrHPV 
and hrHPV and a persistence of hrHPV [12]. These findings are 
supported by those of the meta-analysis by Looker et al., which 
proved that in the presence of HIV infection, the risk of HPV 
acquisition doubles, and for clearance halves, especially with 
a decline in the CD 4 cell count. A threatening observation is 
that similarly to other sexually transmitted diseases, HPV infec-
tion itself may promote the acquisition of HIV infection [7].
However, some authors found the prevalence of hrHPV 
infections and genital malignancies to be similar to that in 
healthy age-matched controls [13, 14] (Tab. 1). 
Table 1. High-risk HPV prevalence
Article Year Reason for immunocompromise
Number of 
patients included hrHPV detected
Most common 
hrHPV subtype
Adebamowo et al. [12] 2017 original HIV + 427 (baseline)321 (after 6 months)
124 (29%)
51 (15.9%)
respectively
Type 52 (8.9%/ 5.5%)
Type 35 (7.0%/4.4%)
Pietrzak et al. [13] 2012 original RTRs 60 11 (15%) —
Origoni et al. [14] 2011 original RTRs/R&PTRs 48 10.5– 27.7 over 10 years of observation —
Roensbo et al. [27] 2018 original RTRs, BMTRs 60 15% (29.4%– BMTRs, 9.3% RTRs) Type 45 (3.3%)
hrHPV — high risk human papilloma virus; RTRs — renal transplant recipients; R&PTRs — renal and pancreas transplant recipients; BMTR — bone marrow transplant recipients
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Another important set of findings that often character-
izes HPV, is that in immunodeficient females the related 
anogenital malignancies are multifocal, and that they may 
develop synchronously or metachronously. It has recently 
been suggested that multifocality in these patients might be 
due to repetitive independent infections with various HPV 
types. This thesis is supported by the fact that in contrast to 
the general population, in which such multifocal lesions usu-
ally contain identical HPV types, in immunocompromised 
females, multiple types of HPV are often detected, even 
including types that are not usually specific for high-grade 
lesions and the types may vary from lesion to lesion within 
the same person [11, 15]. Varying hrHPV subtypes between 
different lesions were reported in 57.1% of patients by 
Meeuwis et al. [11].
HPV PERSISTENCE
Persistent hrHPV infection is a factor that is necessary for 
the development and maintenance of dysplastic lesions and 
their further progression to becoming invasive anogenital 
cancers [16]. Studies with immunocompromised females 
show that these chronic infections are partially linked to 
viral latency. Studies on HIV-positive females have shown 
a significantly reduced likelihood of HPV infection being 
cleared when compared with HIV-negative patients; how-
ever not all the studies indicating this achieved sufficient 
statistical significance to make the findings conclusive [17].
Some studies suggest that in HIV-positive patients, there 
are additional factors, apart from immunosuppression, that 
contribute to the increased prevalence and persistence of 
HPV infections. This might be due to direct interactions of 
the viral genes of HIV and HPV or to changes in reactions of 
the cytokines in cervical mucus to HPV [12].
RISK FACTORS
The risk for developing malignancies is said to be linked to 
the dose and duration of immunosuppression treatments [1]. 
However, some authors suggest that the intensity of a spe-
cific immunosuppression treatment might constitute a more 
important factor in oncogenesis than cumulative doses 
[18]. A recently published study by Mazanowska et al. [19] 
suggests that an hrHPV infection’s prevalence might also 
be influenced by the type of immunosuppressants admin-
istered. For instance, RTRs treated with mammalian tar-
get of rapamycin (mTOR) inhibitors may be less prone to 
developing cervical cancer than those on regimens that 
lack these drugs. Therefore, some authors state that graft 
recipients who are at a particularly high risk of developing 
malignancies could benefit from including mTOR inhibitors 
in their therapy [19]. The connection between the use of 
certain immunosuppressive drugs and the development 
of malignancies was also studied by Madeleine et al. [20].
LESIONS OF THE CERVIX
Infection with hrHPV is a necessary factor in the de-
velopment of cervical intraepithelial neoplasia (CIN) and 
cervical cancer in both immunocompetent and immuno-
compromised individuals: the hrHPV incidence in squamous 
cell carcinoma (SCC) of the cervix is reported to be 100%. 
While the incidence of CIN in RTRs is shown to increase 2- to 
14-fold, the incidence of invasive cervical cancer in RTRs, 
which was previously 3-to-5 times higher than in the general 
population, is now comparable, due to the implementation 
of early screening [3, 11].
The progression of abnormal cervical cytology in immu-
nosuppressed females is observed to be more rapid than in 
healthy controls, while the regression rates in RTRs are signifi-
cantly lower than in the general population. Tanaka et al. [21] 
reported 0% spontaneous regressions of CIN 1 and CIN2 in 
RTRs compared with 68% and 52% respectively in controls. 
AIDS patients are defined as individuals who are HIV 
positive and have either a CD4 cell count below 200/µL 
and/or an AIDS-defining disease, and in 1993, cervical cancer 
became one such disease.
The prevalence of CIN among HIV-positive patients is 
estimated at about 20–40% compared with 3% in the general 
population [22]. Since 2008, British guidelines recommend of-
fering an HIV test to all patients diagnosed with CIN2 or above.
Data on associations between the risk of developing 
cervical cancer and levels of immunosuppression as de-
termined by the CD4 cell count, are inconclusive, as some 
authors observed an increased risk in patients with a lower 
CD4 cell count and others noted no such relation [23, 24].
The influence of highly active antiretroviral therapy 
(HAART) on HPV-related malignancies and HPV infection 
itself is also a matter of controversy. Some authors have re-
ported an increased chance of regression of CIN and clearing 
of HPV infections other than types 16 and 18, while others 
observed no such correlation [10, 23].
VULVAR LESIONS
Histopathologically, most invasive vulvar cancers are 
squamous cell carcinomas (SCC). Together with SCC’s pre-
invasive precursor, vulvar intraepithelial neoplasia (VIN), it 
may be derived either from an HPV-dependent pathway, 
or from an independent pathway. Unlike premalignant and 
malignant lesions of the cervix that are always connected 
with an hrHPV infection, and premalignant and malignant 
lesions of the anus in which the hrHPV infection rate is also 
very high, most vulvar SCC and VIN in the general population 
are hrHPV-free and are observed in women in their 70s, while 
HPV-positive vulvar lesions are less common (20–57%) and 
are observed more frequently among younger females. In 
contrast, the majority of vulvar SCC and VIN discovered 
among immunocompromised females are hrHPV-related; 
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and studies show that these might constitute up to 100% 
of cases. In this group of patients, the woman’s age when 
vulvar cancer is diagnosed, is significantly lower than in 
healthy controls: approximately 40 years old; and this is 
a result of an HPV-dependent etiology [9, 11].
In a study by Meeuwis et al. [3], a 50-fold increased risk for 
developing vulvar SCC was detected in a cohort of RTRs. The 
study found that the most common HPV types in vulvar le-
sions in both immunocompetent and immunocompromised 
patients were type 16 (60% vs 50% respectively) and 33 (20% 
vs 17% respectively), while the other types described in vul-
var lesions in the general population are 18, 52 and 58. Type 
58 also occurred in 17% of the vulvar neoplasms of RTRs 
in the cohort studied by Meeuwis et al. [11]. Studies have 
shown that vulvar cancer usually develops between 10- and 
20-years following transplantation, which might suggest 
that its development requires prolonged HPV infection [5].
A meta-analysis study by Grulich et al., comparing 
the incidence of malignancies between population of 
HIV/AIDS patients and solid organ recipients, suggested 
there is a higher risk of developing vulvar cancer in the 
latter population [2].
Interestingly, the incidence of VIN (but not invasive 
vulvar cancer) and anal intraepithelial neoplasia (AIN) in 
organ recipients was observed as increasing in patients who 
had received a transplant for the second time. The authors 
also noted a significant rise in the incidence of vulvar cancer 
in pancreas transplant recipients [20]. 
VAGINAL LESIONS
The number of vaginal intraepithelial neoplasia (VaIN) 
is observed to increase. These lesions are often diagnosed 
simultaneously to VIN and CIN [3]. 
ANAL LESIONS
Most anal cancers, in both immunocompetent and immu-
nocompromised patients, are SCC. AIN is similar to CIN. Mostly, 
both invasive and preinvasive anal lesions are HPV-depend-
ent; and therefore, immunocompromised patients are also at 
a higher risk of their development. In the general population, 
anal cancer constitutes about 1.5% of cancers, while in the 
cohort of RTRs studied by Meeuwis et al. [11], the increased 
risk of this cancer was estimated to be approximately 122-fold. 
Studies show that risk factors for developing anal cancer are 
anoreceptive intercourse, previous diagnosis of an HPV-re-
lated cervical or vulvar cancer, and condylomata acuminata.
The detection rate for HPV infections in invasive anal 
cancer is 71–92.2% in the general population [11]. HPV 
subtype 16 is the most prevalent, and is detected in 66.7% 
of patients, followed in prevalence by subtypes 18 and 33.
HIV-positive females are said to have a 35-fold higher 
chance of developing anal cancer when compared with 
HIV-negative controls. Also, in a meta-analysis by Grulich 
et al. [2], HIV/AIDS patients proved to be at a significantly 
higher risk of developing anal cancer when compared with 
subjects who were immunosuppressed because of solid 
organ transplantation.
Furthermore, a higher risk of developing anal high grade 
squamous intraepithelial lesions (HSIL) was observed in HIV 
positive patients who had undergone solid organ transplan-
tation, regardless of the organ type transplanted or use of T 
cell depleting medications. No further studies have yet been 
performed on this group of patients [25]. 
PRIMARY PREVENTION
As the incidence of HPV infections, and the overall risk 
of developing HPV-related premalignant and malignant 
lesions of the anogenital region in immunocompromised fe-
males increases, actions should be taken in order to prevent 
these infections. Patients should be educated on anogenital 
cancer risk factors and vaccination should be recommended. 
The effectiveness of vaccination in anogenital cancer pre-
vention in the general population is already well-proven. 
However, there is limited data on HPV vaccines in immu-
nosuppressed females. The safety and immunogenicity of 
these vaccinations have already been proved in the popula-
tion of HIV-1 infected women [26]. Further research is need-
ed to determine whether vaccine-induced immunity against 
HPV persists in immunocompromised patients in contrast 
to vaccine-induced hepatitis B immunity which has been 
reported as declining over time in this group of patients [5]. 
Recently published data by Cespedes et al., on the response 
of HIV-1 positive females to a quadrivalent HPV vaccine, 
are promising. The data suggest that despite the gradual 
decline in antibody titers, seropositivity was sustained until 
72 weeks post-vaccination for all subtypes except for type 
18, in a cohort of patients with CD4 ≤ 200 cells/mm3 [6]. 
Moreover, it is worth noting that as infections with 
hrHPV types other than subtype 16 and 18 and multitype 
infections are both discovered particularly frequently in im-
munocompromised patients, these patients would probably 
benefit most from the nonavalent vaccine against types 
6, 11, 16, 18, 31, 33, 45, 52 and 58 that was approved in 
2014 [27]. In a study by Cespedes et al. [6], the nine hrHPV 
types listed above accounted for 63% of cervical and 64% 
of anal HPV types detected. 
Studies have also been conducted to assess the thera-
peutic effectiveness of HPV vaccinations in the population 
of immunosuppressed patients [28].
SECONDARY PREVENTION
Despite a lack of hard evidence, but due to a generally 
accepted increase in the prevalence of hrHPV infections and 
the higher risk of developing anogenital malignancies in 
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immunosuppressed females, both the American Society of 
Transplantation (in 2000) and the Expert Group on Renal 
Transplantation (in 2002), recommended annual cervical can-
cer screening, including Pap smears and pelvic examinations 
in this group of patients [29, 30]. According to the literature, 
insufficient annual screenings are being carried out: Kerkhoff 
et al. [31] described an overall 16% uptake of annual screen-
ings in the Republic of Ireland and that in 26% of RTRs there 
was no screening at all. Similarly, in the Northern Ireland 
study by Courtney et al. [32], the overall uptake was 10% and 
32% of RTRs had no screening. The uptake of cervical screening 
in underprivileged countries is clearly even lower. Nega et al. [28] 
reported a 10% lifetime uptake of cervical screening in Ethio-
pia among HIV positive females, and 93.4% of those were 
only screened after the diagnosis of HIV.
Some authors proclaim postponing the implementation 
of annual screenings until approximately 3 years following 
transplantation in patients with a normal pretransplanta-
tion screening result because most malignancies are de-
tected several years after transplantation (e.g., according to 
Meeuwis et al. [3], detection is 9 years after RT). This matter 
requires further investigation.
SELF-SAMPLING
As the participation of immunocompromised patients 
in gynecological screening has proved to be low, despite 
recommendations for annual checkups, a novel method of 
HPV testing based on self-sampling was recently introduced 
in order to increase the detection of anogenital malignan-
cies. It has been shown that giving nonresponders the op-
portunity to self-collect the specimen for hrHPV testing has 
increased their willingness to participate in the screening 
program. Various self-collection devices were tested, such 
as tampons, brushes, lavages and swabs. While tampons 
seem to be the most preferred device (probably as patients 
are most familiar with them) according to some authors, 
the self-collection device most researchers recommend is 
the cervicovaginal brush. These latter have proved to be 
well-accepted by females, have demonstrated a greater 
sensitivity for CIN detection than swabs, require less process-
ing than tampons, may be transported and stored in a dry 
state, in contrast to lavages, and may therefore be delivered 
by mail, thus expanding the participation possibilities for 
screening programs [33]. It was proved that the sensitivity 
of self-collected vaginal samples is comparable with that of 
cervical samples [34].
TREATMENT
When diagnosing a malignancy in an immunocompro-
mised patient, healthcare providers face additional factors 
that need to be taken into consideration when planning 
a therapy. In solid organ recipients the possible therapeutic 
options are greatly influenced by the need to preserve the 
graft’s function. This relates mostly to surgery and radio-
therapy. The location of graft in the pelvis, especially in RTRs, 
limits both the possibility of radical surgery with extensive 
lymphadenectomy and of radiotherapy [35]. For these rea-
sons, oncologic treatment of solid organ recipients often has 
to be limited and therefore, mortality rates among invasive 
cancer cases are high. This latter emphasizes the need for 
primary and secondary prevention that enable early stage 
detection of the malignancy. 
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